TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Paclitaxel, Carboplatin and Vorinostat for the Treatment of Advanced Stage Ovarian Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with a histologic or cytologic diagnosis of stage III/IV ovarian cancer, fallopian tube epithelial cancer, or peritoneal cancer who have not received prior chemotherapy or radiotherapy.~* Subjects must have the appropriate surgery for their gynecologic cancer. However, subjects may be treated in a neoadjuvant manner, with surgery being performed after chemotherapy cycles 1, 2, or 3.~* If neoadjuvant therapy is not administered, subjects must receive their first dose no more than six weeks postoperatively.~* Subjects must have adequate bone marrow, renal and hepatic function as defined by WBC \> 3,000 cells/cu ml., platelets \> 100,000/cu.ml., calculated creatinine clearance \> 50 ccs/min., bilirubin \< 1.5 mg/dl, and SGOT \< three times normal.~* Karnofsky performance status \> 50%.~* Subjects who have signed an institutional review board (IRB) approved informed consent form.~Exclusion Criteria:~* Subjects with epithelial ovarian cancer of low malignancy potential.~* Subjects with septicemia, severe infection, or acute hepatitis.~* Subjects with a history of congestive heart failure, angina, or a history of myocardial infarction within the past six months.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vorinostat (Type: EXPERIMENTAL): All study patients will receive the indicated dose of Vorinostat in conjunction with paclitaxel and carboplatin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Aliskiren Effect on Aortic Plaque Progression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: Patients, both males and females, were eligible if they were ≥ 45 years of age, with previously documented cardiovascular disease, defined as at least one of the following: myocardial infarction (MI), cerebrovascular accident (CVA), coronary bypass surgery and/or percutaneous intervention, peripheral arterial disease (PAD), defined as ankle brachial index (ABI) \<0.9 and/or prior peripheral intervention/surgery. Subjects on angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blockers (ARB) therapy were eligible to participate, provided no dose adjustments were made during the course of the study.~Exclusion Criteria: Contraindications to the MRI exam (pacemakers, metallic implants, severe claustrophobia); diagnosis of Type II Diabetes or use of hypoglycemic drugs; uncontrolled hypertension (\>145/90 mm Hg); low density lipoprotein (LDL) of ≥ 130mg/dL; renal insufficiency defined as glomerular filtration rate (GFR) ≤ 40 ml/minute (derived by the Modified Diet in Renal Disease (MDRD) equation); initiation of new therapy with statins, ACEI/ARBs, anti-oxidants, calcium channel blockers, diuretics, β blockers; transient ischemic cerebral attack during the prior 6 months; history of allergy to renin inhibitors; unstable cardiac syndromes; symptomatic arrhythmias; history of malignancy including leukemia and lymphoma (but not basal cell skin cancer, cured squamous cell cancer and localized prostate cancer) and history of allergy to renin inhibitors.

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aliskiren (Type: ACTIVE_COMPARATOR): Aliskiren will be administered for 2 weeks at 150mg/day oral pill, followed by 34 weeks oral therapy with 300mg/day
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (sugar pill) built to mimic both the 150mg Aliskiren tablet ( administered for the first 2 weeks) and the 300mg Aliskiren tablet ( administered for the rest of treatment period)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison Between Desmopressin and Fesoterodine for Treatment of Night Time Voiding in Women Aged 65 and Older

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Menopausal female patients aged 65 years and older~* Patients with severe nocturia, defined as waking to void 3 or more times at night due to an urge to void~* Patients capable of understanding and having signed the consent form after full discussion of the research, nature of the treatment, its risks and benefits~Exclusion Criteria:~* Urinary tract infection or chronic inflammation such as interstitial cystitis and bladder stones~* Urinary and gastric retention~* Narrow-angle glaucoma~* von Willebrand's disease~* Chronic severe constipation or history of gastrointestinal obstructive disease~* Untreated congestive heart failure and venous insufficiency~* Untreated hypertension or tachycardia~* Untreated renal or liver disease~* Untreated diabetes mellitus or insipidus~* Unexplained and untreated electrolyte disturbances~* Any clinical condition which in the opinion of the investigator would not allow safe completion of the study~* Current use of diuretics with untreated electrolyte disturbances~* Patients taking drugs known to be strong CYP3A4 inhibitors (protease inhibitors, ketoconazole, clarithromycin) or strong CYP3A4 inducers (carbamazepine, phenytoin, St. John's Wort) used on a regular basis~* Patients taking anticholinergic or antispasmodic medications who did not comply with a minimum 14 days washout period~* Previous failed therapy with Fesoterodine or Desmopressin~* Hypersensitivity or intolerance to Fesoterodine or Desmopressin~* Hypersensitivity to soya, peanuts or lactose~* Clinically significant outlet obstruction as determined by the investigator~* Patients with Post Void Residual (PVR) \> 100 ml~* Patients with Mini-Mental State Exam (MMSE) \<24

- Gender: FEMALE
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Desmopressin (Type: ACTIVE_COMPARATOR): Patients randomized to receive Desmopressin will be given 0.1mg daily by mouth at bedtime. After 4 weeks, patients will have the option to increase their dose to 0.2mg daily by mouth at bedtime. Total time of drug administration will be 12 weeks.
- Fesoterodine (Type: ACTIVE_COMPARATOR): Patients randomized to receive Fesoterodine will be given 4mg daily by mouth at bedtime. After 4 weeks, patients will have the option to increase their dose to 8mg daily by mouth at bedtime. Total time of drug administration will be 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison Study of Wound Closure at Time of Cesarean Delivery: Dermabond Glue Versus Surgical Staples

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant women undergoing scheduled and non-scheduled cesarean deliveries~Exclusion Criteria:~* Prisoners~* Insulin-requiring diabetics~* Vertical skin incision~* Allergy to Dermabond

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Women receiving Dermabond for skin closure
- 2 (Type: ACTIVE_COMPARATOR): Women receiving standard surgical skin staples

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Fertility Preservation- Oncology Treatment Effects and Psychological Impact

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Women ages 18-45~* Women seeking fertility preservation at WCMC~* Women who will undergo oncology treatments that will likely cause reduced fertility potential.~Exclusion Criteria:~* Women who do not meet the inclusion criteria

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Effect of One-lung Ventilation on BIS Values

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients coming for thoracic surgery with anticipated need for lung isolation~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Opening Wedge High Tibial Osteotomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pain: Subjective pain in the knee most of the month for at least one month during past 12 months.~* Knee range of motion (ROM) at least 5-120 degrees~* X-ray: medial joint space Altman \> 1. Lateral joint space Altman \< 2.~* Mechanical axis \> 3 degrees varus alignment.~* Medial proximal tibial angle (MPTA) \< 90 degrees~* age 25-55.~* Written consent, accepts both treatment arms.~Exclusion Criteria:~* Pain is caused by something else than medial knee osteoarthrosis~* deficient ROM (flexion contracture \> 10 degrees, flexion \< 110 degrees)~* significant ligament instability~* post traumatic OA~* clinically relevant neurological disease (e.g. Alzheimer´s disease)~* clinically relevant metabolical disease (e.g. Diabetes)~* alcohol/drug abuse~* infectious/inflammatory joint disease~* previous knee area osteotomy or lower limb arthroplasty~* smoking (\> 0 cigarette per day)~* obesity (BMI \> 33)~* pregnancy or hope of pregnancy in the following two years

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- HTO-group (Type: ACTIVE_COMPARATOR): Group receives opening wedge high tibial osteotomy with Tomofix -plate. Operative intervention is followed by supervised physiotherapeutic rehabilitation.
- FT -group (Type: ACTIVE_COMPARATOR): Group receives only supervised physiotherapeutic rehabilitation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients planning to undergo HCT or other cellular therapy/immunotherapy~* Allogeneic related donors~* Aged 0-80~* Willing and able to sign voluntary written consent~Exclusion Criteria:~* Patients whose medical record indicates that they have opted out of research

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Immune and Microbial Reconstitution (Type: None): None
- Immune Response Triggered by Severe, Systemic Viral Infection (Type: None): None
- Immune Response Triggered by Acute Graft-versus-Host Disease (Type: None): None
- Immune Response Triggered by Chronic Graft-versus-Host Disease (Type: None): None
- Immune Response Triggered by Relapse (Type: None): None
- Immune Response Triggered by Cytokine Release Syndrome (Type: None): None
- Allogeneic Related Donor Samples (Type: None): None
- Cellular Therapy Products (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Using a Humanoid Robot to Distract Children With Chronic Conditions Undergoing Painful Procedures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~All participants:~* Chronic disease~* Willing to participate and comply with pre-determined interventions~* 8-12y (children)~* Child and parent(s)/guardian cohabited for the past 5 years or, in case of divided custody, for at least half of the child's lifetime~* Currently being treated (not necessarily hospitalized) in the University Hospital Brussels~Exclusion Criteria:~* Developmental disabilities (e.g.: autism spectrum disorder, Attention Deficit (Hyperactivity) Disorder)~* Psychiatric disorders (e.g.: anxiety disorder, personality disorder)~* Significant vision or hearing impairment~* Not able to read and speak fluent Dutch (parent and child)

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Usual care group (control group) (Type: ACTIVE_COMPARATOR): Within the usual care, no one of the attendees in the room will have specific interaction with the child during this procedure, with the exception of normal/necessary interaction by the nurse and/or parent. Only minimal distraction is allowed. The child will sit down on the treatment table with the legs stretched out in front of him and the puncture-side arm in a 90-90 position next to the head or stretched out and lying down along the body, with the nurse at the puncture side and the parent at the other side standing next to him. The researcher is also present in the room, within the child's field of vision. At the end of the procedure, the nurse tells the child that he/she did very well.
- Robot-assisted puncture procedure (experimental group) (Type: EXPERIMENTAL): During the experimental intervention, the child, a nurse, one of the parents/guardians, a researcher and the humanoid robot NAO (H25 Academic Edition, Aldebaran Robotics, Paris, France) will be present in the same room. The child will sit down in the same position as with the usual care. Next to the patient a humanoid robot of three-foot tall will sit on eye level on a slanted reading table, at the non-puncture side. The nurse will carry out the puncture procedure as performed as usual. The robot is programmed to distract the child during the entire procedure (before, during and after the puncture) by playing a game with the child based on his/her interests. The child can therefore choose between a number of games in different themes. In the end the robot tells the child that he/she did very well. During the whole intervention, the robot will be re-activated for each phase only when the child and the nurse are ready.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Short Term, High Dose Atorvastatin Therapy on Periprocedural Myonecrosis and Platelet Inhibition After Percutaneous Coronary Intervention (PCI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients undergoing revascularization for significant coronary artery disease~* age range 21-85 years~Exclusion Criteria:~* non-STEMI, STEMI~* cancer~* renal failure with creatinine\>3.0mg/dl~* liver cirrhosis~* lymphoproliferative disorder~* pregnancy~* thrombocytopenia\<150'000~* coagulopathy (INR\>1.5)~* abnormal liver function tests~* illicit drug use~* history of statin intolerance~* history of rhabdomyolysis~* planned use of Glycoprotein IIb/IIIa inhibitors during PCI~* current therapy with atorvastatin, pravastatin, lovastatin, fluvastatin, or rosuvastatin

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- No atorvastatin (Type: NO_INTERVENTION): Patients do not receive Atorvastatin prior to PCI in cath lab
- atorvastatin (Type: EXPERIMENTAL): Atorvastatin 80mg po given prior to PCI in cath lab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of ARC1779 on Cerebral Microembolism in Patients Undergoing Carotid Endarterectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients;~* \>/= 18 to \</= 80 years of age;~* Carotid stenosis (either symptomatic or asymptomatic);~* Planned carotid endarterectomy;~* Female patients must be non-pregnant and willing to use effective, redundant methods of contraception (i.e., for both self and male partner) throughout the study and for at least 30 days after discontinuation of study drug treatment;~* Male patients must agree to use a medically acceptable contraceptive (abstinence or use of a condom with spermicide) throughout the study and for at least 30 days after discontinuation of study drug treatment;~* All patients must be capable of understanding and complying with the protocol and must have signed the informed consent document.~Exclusion Criteria:~* Lack of acoustic window allowing TCD recordings;~* Unable or unwilling to consent;~* Metallic prosthetic cardiac valve;~* Recent (\<4 weeks) ischemic stroke involving \>1/3 of the MCA territory;~* Any history of hemorrhagic stroke;~* Thrombocytopenia;~* Coagulopathy;~* Trauma or surgery within preceding 30 days;~* History of bleeding disorder, gastrointestinal ulcers, or other medical problem associated with an increased risk of bleeding;~* Use of warfarin and any chronic antithrombotic therapy other than acetylsalicylic acid and/or dipyridamole; patients previously treated with warfarin are eligible if the drug has been discontinued and the INR prior to randomization has returned to \<1.3;~* Use of clopidogrel, unless it has been discontinued at least 5 days prior to randomization;~* Fibrinolytic or GPIIb/IIIa inhibitor treatment within the preceding 24 hours.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): ARC1779 Injection
- 2 (Type: PLACEBO_COMPARATOR): Placebo (normal saline)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: 2021 PMT iAge® Intervention Trial by Edifice Health

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18+ years old~* Ambulatory~* Willing and able to comply with the study protocol~Exclusion Criteria:~* Participants with any condition that may preclude venipuncture or venous blood draws will be excluded.~* Participants with known allergies to interventions will be removed from the study.~* Vulnerable subjects including children, employees and those with cognitive disabilities will not be included in this study.~* Male participants on iron supplementation~* Participants on \>1 mg manganese, \>5 mg biotin~* Pregnant women~* Nursing women~* Membership in the clinical study team~* Any condition that might interfere with volunteer safety, study objectives or the ability of the participant to understand or comply with the study protocol~At the time of enrollment:~* Active systemic or serious concurrent illness~* History of immunodeficiency~* Any known or suspected impairment of immunologic function~* Diabetes mellitus treated with any diabetic medication~* Moderate to severe renal disease~* Blood pressure greater than 140/90~* Chronic hepatitis B or C~* Recent or current use of immunosuppressive medication~* Malignancy other than squamous cell or basal cell skin cancer, including solid tumors such as breast cancer or prostate cancer with recurrence in the past year, and any hematologic cancer such as leukemia, which might jeopardize volunteer safety or compliance with the protocol~* Autoimmune disease~* Auto-inflammatory disease~* History of blood dycrasias or hemoglobinopathies requiring regular medical follow up or hospitalization during the preceding year~* Use of any anticoagulation medication~* A medical or psychiatric condition or occupational responsibilities that would preclude subject compliance with the protocol~* History of Guillain-Barre syndrome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Dietary supplements (Type: ACTIVE_COMPARATOR): Dietary supplements are either (1) designated as Generally Recognized As Safe (GRAS) by the Food and Drug Administration or (2) compounds at similar concentrations to those found in foods.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo-matched formulations

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy